CliffBio
biologic

Lunsumio

mosunetuzumab-axgb

Loss of exclusivityDecember 2034projected — 12-year biologic exclusivity estimate
CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand nameLunsumio
Active ingredientmosunetuzumab-axgb
Strength1MG/ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2022
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Lunsumio patent cliff — loss of exclusivity December 2034 | CliffBio